Optimizing CD4 + T Cells Long-Term Expansion Process In The DASbox ® Mini Bioreactor System

By Silvia Tejerina Vargas, Vincent Dufey, Aurélie Tacheny, Françoise De Longueville, Eppendorf Application Technologies S.A., Namur, Belgium

Several adoptive cell therapies have received approval from the US Food and Drug administration (FDA), all of them involving the use of CAR T cells. The development of efficient and high-quality cell therapy products however continues to be a challenge for clinical researchers and health care providers with the determination of optimal cell culture conditions to achieve high-quality cells and the production of sufficient cell quantities in a rapid time frame as key goals at the R&D stage. Stirred-tank bioreactors successfully offer a suitable environment for the culture of T cells. We outline the impressive use of stirred-tank bioreactors to efficiently expand T cells from different donors.